• EnglishEnglish
    • Deutsch Deutsch
    • Italiano Italiano
    • Français Français
    • 日本語 日本語
    • 한국어 한국어

CISEMA - China Zertifizierung, Einkauf und Qualitätssicherung

  • Services
    • NMPA Registration – Medical Devices and IVDs
    • NMPA Registration & DMF – Pharmaceuticals
    • NMPA Registration – Cosmetics
    • NMPA Registration – Health Food
    • CML (China Manufacture Licence) – Pressure vessels
    • CCC (China Compulsory Certification) – Industrial and consumer goods
    • Others
      • Sourcing and Quality Control
      • Logistics and Customs Support
      • Sales Support
  • About us
    • Partners
    • Company Profile
    • Testimonials
  • Locations
  • Events
    • Trade Fairs & Conferences
    • Seminars
    • Webinars
  • News & Knowledge
    • Regulatory News
      • Medical Devices and IVDs
      • Cosmetics
      • Pharmaceuticals & DMF
      • CCC
      • Pressure Vessels
    • Whitepapers
    • FAQ – NMPA Registration – Medical Devices and IVDs
    • Newsletter Sign Up
    • Others
      • Publications
      • Online Shop
Contact
  • Home
  • News
  • News
  • NMPA Registration in China
  • Medical Device
  • New NMPA Measures for Random Medical Device Checking In-market

New NMPA Measures for Random Medical Device Checking In-market

Friday, 20 March 2020 / Published in Medical Device

New NMPA Measures for Random Medical Device Checking In-market

On 13.03.2020, the NMPA announced (No.09-2020) the Administrative Measures for the Sampling Inspection on the Quality of Medical Devices. This is a new measure designed to increase NMPA’s post-market surveillance and applies to all registered medical devices sold in China.

According to the administrative measures, the NMPA focus is on conducting sampling inspections on medical devices in the market including, but not limited to, those medical devices with the following features:

1. with high safety risks and requiring special supervision;
2. involving a high dosage amount, a wide population of users, and a wide range of uses;
3. for which many complaints have been received and public concerns have been raised;
4. where adverse event reporting indicates possible quality issues; or
5. for which product quality is easily affected by the conditions of storage and transportation.

On the contrary, the provincial MPAs will focus their sampling inspection on medical devices including, but not limited to, those medical devices with the following features:

1. where the product has been registered or filed within the relevant provincial administrative area;
2. with relatively high safety risks and not otherwise included in the list of product categories for inspection;
3. listed in the previous year’s sampling inspection plan, but not yet inspected; or
4. for which daily monitoring and adverse event reporting indicates possible quality issues.

The NMPA legal agents are required to fully cooperate throughout the inspection process for imported medical devices. If there is any objection to the inspection results, the application for re-inspection must be submitted within 7 working days after the issued date of the inspection report.

Tagged under: Sampling Inspection

What you can read next

China medical device sampling inspection results
China medical device sampling inspection results no.4 of 2022
CMDE Analyzes the Typical Issues for Combination Product Registrations
3 Cosmetics Draft Regulations Issued for Public Consultation

Search

Categories

  • Fairs & Events
  • News
    • CCC
    • CEL
    • CML, SELO
    • Medical Devices Listing in Hong Kong
    • NMPA Registration in China
      • Cosmetics
      • Health Food
      • Medical Device
      • Pharmaceuticals & DMF
    • RoHS
    • Voluntary Product Certification
  • Publications
  • Seminars
  • Uncategorized
  • Webinars

Recent Posts

  • China medical device sampling inspection results

    China medical device sampling inspection results no.4 of 2022

    China medical device sampling inspection result...
  • NMPA cosmetic sampling inspection

    The NMPA Cosmetic Sampling Inspection measures come into force on March 1, 2023

    NMPA Cosmetic Sampling Inspection Measures come...
  • China cosmetics quality safety responsibilities

    China cosmetics quality and safety responsibilities regulations released

    China cosmetics quality and safety responsibili...
  • China cosmetics efficacy claims FAQ

    China cosmetics efficacy claims FAQ available to answer key questions

    China cosmetics efficacy claims FAQ is availabl...
  • China cosmetics GMP inspections

    China cosmetics GMP inspections points have been finalised

    China cosmetics GMP inspections points and judg...

Archive

Cisema

With twelve locations and over ninety highly qualified employees, Cisema can offer you optimal support in China.

Services

  • Certification
  • Sourcing and Quality Control
  • Logistics and Customs Support
  • Sales Support

Dialogue

  • Contact us
  • Newsletter Signup
  • Events
  • News & Knowledge
  • Partners

Company

  • GTC
  • Privacy Statement
  • Legal Notice
  • About us
  • Locations
  • GET SOCIAL

© 2021 Cisema. All rights reserved.

TOP
Cookies on Cisema
Learn more about Cisema's Privacy Policy.